

conditions, such as the transformation of normal cells to tumor cells. The FUSE-binding protein also may be used for developing mAbs that can be used to detect and quantitate the protein in biologic samples.

Fluorescent Hybridization Probes not Requiring Separation of Products

ME Hawkins, W Pfliegerer, MD Davis, FM Balis (NCI)
U.S. Patent 5,525,711 issued 11 Jun 96;
U.S. Patent 5,612,468 issued 18 Mar 97; DHHS Reference No. E-155-96/1;
PCT/US97/22448 filed 10 Dec 97
Licensing Contact: L. Manja R. Blazer;
301/496-7056 ext. 224; e-mail:
mb379c@nih.gov

Fluorescent guanosine analogs (excitation at 340 nm, emission at 450 nm) are incorporated into oligonucleotides through a native deoxyribose linkage using automated DNA synthesis which allows them to base stack with native bases. As a result, slight changes in DNA structure can cause significant changes in spectral properties. These compounds are highly fluorescent as monomers in solution, but lose intensity in oligonucleotides. The use of these fluorophores as hairpin hybridization probes is based on the dramatic fluorescence increase that occurs upon them being squeezed out of the strand during annealing where the probe has not been provided with a base-pairing partner in the complementary strand. The degree of increase depends on the oligonucleotide sequence and the annealing strands' concentration. It allows the detection of specific DNA sequences in a mixture without separation of annealed and labeled products. These stable probes are treated as normal phosphoramidites during the DNA synthesis and subsequent de-blocking procedures.

This research has been published in *Nucleic Acids Research*, 23 (1995) 2872-2880 and *Analytical Biochemistry*, 244 (1997) 86-95.

Dated: January 13, 1999.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.
[FR Doc. 99-1424 Filed 1-21-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(4) and 552b(c)(6), Title U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel, Shared Resources for Scientists Outside NCI Cancer Centers.

Date: February 17, 1999.

Time: 8:00 am to 6:00 pm.

Agenda: To review and evaluate grant applications.

Place: Ramada Inn Rockville, 1775 Rockville Pike, Rockville, MD 20852.

Contact Person: Sherwood Githens, PhD, Scientific Review Administrator, National Institutes of Health, National Cancer Institute, Special Review, Referral and Resources Branch, Executive Plaza North, 6130 Executive Boulevard, Bethesda, MD 20892, 301/435-9050.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: January 14, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 99-1427 Filed 1-21-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should

notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Acquired Immunodeficiency Syndrome Research Review Committee.

Date: February 18-19, 1999.

Open: February 18, 1999, 8:00 am to 9:00 am.

Agenda: The meeting will be open for discussion of administrative details relating to committee business and program review, and for a report from the Director, Division of Extramural Activities, which will include a discussion of budgetary matters.

Place: Wyndham Washington Hotel, 1400 M Street NW, Washington, DC 20005-2750.

Closed: February 18, 1999, 9:00 am to adjournment on February 19, 1999.

Agenda: To review and evaluate grant applications.

Place: Wyndham Washington Hotel, 1400 M Street NW, Washington, DC 20005-2750.

Contact Person: Paula S. Strickland, PhD., Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, NIAID, NIH, Solar Building, Room 4C02, 6003 Executive Boulevard MSC 7610, Bethesda, MD 20892-7610, 301-402-0643.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: January 14, 1999.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc 99-1425 Filed 1-21-99; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Council on Drug Abuse.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign